Bio-Rad
Bio-Rad Again Lowers Guidance After Q3 Revenue Miss, Sharp Sales Decline in Life Science Segment
Premium
The firm plans to stay the course on its long-term company transformation goals despite the imminent departure of its chief financial officer, one of the plan's architects.
New data has demonstrated that DNA fragment size differences that discriminate preeclampsia from healthy controls can be detected using a lower-cost PCR method.
The company's Life Sciences segment revenues fell 7 percent, while Clinical Diagnostic revenues rose 3 percent.
In Brief This Week: AACC; Siemens Healthineers; Bio-Rad; T2 Biosystems; DermTech; More
News items for the week of July 17, 2023.
The firm said overall it remains on track for a previously described transformation and new instrument launches.
Feb 17, 2023
Bio-Rad Q4 Revenues Flat, Miss Analyst Estimates
Oct 28, 2022
Jul 29, 2022
Feb 11, 2022
Bio-Rad Q4 Revenues Fall 7 Percent
Oct 12, 2021